DNA-drug Conjugates for Site-specific Delivery in Anti-cancer Therapy

Author(s): Karimpanakkal C. Ajithkumar, Kannissery Pramod*

Journal Name: Current Pharmacogenomics and Personalized Medicine
Formerly Current Pharmacogenomics

Volume 14 , Issue 2 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Background: Many drugs when conjugated with DNA by covalent or noncovalent interaction form highly reactive, site specific delivery species called drug-DNA adduct.

Objective: The objective of the present review is to highlight the importance and utility of DNA – drug conjugates for site-specific delivery in anti-cancer therapy.

Results: Drugs, such as doxorubicin, cisplatin, ellipticine, melphalan, tamoxifen, etc. were reacted with endosomal formaldehyde to form an intermediate Schiff base. The Schiff base can successfully interact with the exocyclic amino group of guanine nucleotides, resulting in drug-DNA adducts through the aminal linkage. This mechanism has been extended to in vitro adduct formation of anthracycline drugs with deoxyguanosine group of DNA, which is highly stable at low temperature and in physiological pH.

Conclusion: The adduct would gradually release the drug at a physiological temperature and is thus well suited for site-specific targeted drug delivery with reduced side effects.

Keywords: Drug conjugated DNA, deoxyguanosine, doxorubicin, guanine residue, site-specific, targeting.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [68 - 73]
Pages: 6
DOI: 10.2174/1875692115666170208121925
Price: $25

Article Metrics

PDF: 67